Immatics
assessment of anti tumor activity in | Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
52 of 75
Related slides by other companies
Imara
Mergers and Acquisitions
October 2022
demonstrated robust anti tumor activity in her intracranial model at well tolerated doses | Imara
Genelux
Investor Presentation
December 2023
phase anti tumor activity as leading into combination a | Genelux
IHG Hotels
Results
February 2022
fee based business model shows relative resilience as demand returns | IHG Hotels
Boundless Bio
IPO
March 2024
demonstrated synergistic combination activity in preclinical models of cancer indications in which single agent targeted therapies have not proven effective in the clinic eye | Boundless Bio
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights